As of Jun 22, 2026, the Illumina stock's P/E ratio is 29.24. This takes into account the latest EPS of $5.52 and stock price of $161.38. The PE ratio has increased by 49% from its last 4 quarters average of 19.6.
The PE ratio of Illumina has averaged 53.83 over the last ten years. The current price-to-earnings ratio of 29.24 is 46% less than the historical average. Analyzing the last ten years, ILMN's PE ratio reached its highest point in the Jul 2021 quarter at 90.25, when the price was $474.73 and the EPS was $5.26. The lowest point was recorded in the Jun 2025 quarter, when it reached 11.97 with a price of $94.79 and an EPS of $7.92.
Maximum annual increase: 147.99% in 2013
Maximum annual decrease: -34.67% in 2014
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 24.67 | N/A | $134.95 | $5.47 |
| 2024 | N/A | N/A | $135.27 | -$7.69 |
| 2023 | N/A | N/A | $139.24 | -$7.34 |
| 2023 | N/A | N/A | $202.2 | -$28 |
| 2022 | 75.04 | -9.14% | $380.44 | $5.07 |
| 2021 | 82.59 | 69.28% | $370 | $4.48 |
| 2019 | 48.79 | -7.89% | $332.29 | $6.81 |
| 2018 | 52.97 | 20.25% | $298.23 | $5.63 |
| 2017 | 44.05 | 6.3% | $218.49 | $4.96 |
| 2017 | 41.44 | -31.13% | $128.04 | $3.09 |
| 2016 | 60.17 | -16.56% | $191.95 | $3.19 |
| 2014 | 72.11 | -34.67% | $188.2 | $2.61 |
| 2013 | 110.38 | 147.99% | $110.38 | $1 |
| 2012 | 44.51 | 2.23% | $54.75 | $1.23 |
| 2012 | 43.54 | -30.57% | $30.48 | $0.7 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 21.32 | -13.58% | $117.67 | $5.52 |
| Dec 2025 | 24.67 | 20.28% | $134.95 | $5.47 |
| Sep 2025 | 20.51 | 71.35% | $91.69 | $4.47 |
| Jun 2025 | 11.97 | N/A | $94.79 | $7.92 |
| Mar 2025 | N/A | N/A | $80 | -$6.05 |
| Dec 2024 | N/A | N/A | $135.27 | -$7.69 |
| Sep 2024 | N/A | N/A | $130.12 | -$9.95 |
| Jun 2024 | N/A | N/A | $104.38 | -$19.15 |
| Mar 2024 | N/A | N/A | $137.32 | -$8.15 |
| Dec 2023 | N/A | N/A | $139.24 | -$7.34 |
| Oct 2023 | N/A | N/A | $137.28 | -$7.1 |
| Jul 2023 | N/A | N/A | $187.49 | -$26.59 |
| Apr 2023 | N/A | N/A | $232.55 | -$28.51 |
| Jan 2023 | N/A | N/A | $202.2 | -$28 |
| Oct 2022 | N/A | N/A | $190.79 | -$26.43 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, ILMN's PE ratio is under its 5 and 10-year averages.
Illumina's price to earnings (P/E) of 29.24 is higher than the Healthcare sector and its peers average but lower than the industry average. Looking at the Healthcare sector average of 24.1, Illumina's price to earnings (P/E) is 21% higher.
When compared to its peer DHR, ILMN's PE ratio is lower, but it is higher than TMO's and A's. Illumina's PE ratio is trading above the peer average of 26.55.
| Stock name | PE ratio | Market cap |
|---|---|---|
| DGX Quest Diagnostics Inc | 21.11 | $21.43B |
| A Agilent Technologies Inc | 25.3 | $35.72B |
| TMO Thermo Fisher Scientific Inc | 25.47 | $172.44B |
| ILMN Illumina Inc | 29.24 | $24.42B |
| DHR Danaher Corp | 34.33 | $126.12B |
| PACB Pacific Biosciences Of California Inc | N/A | $409.99M |
As of Jun 22, 2026, ILMN stock has a price to earnings ratio of 29.24.
The 5-year average PE ratio for ILMN stock is 48.43.
Over the last ten years, the quarterly PE ratio reached its highest level at 90.25 in the Jul 2021 quarter.
ILMN's price to earnings ratio is currently 46% below its 10-year historical average.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jun 22, 2026), Illumina's share price is $161.38. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $5.52. Therefore, Illumina's price to earnings ratio for today is 29.24. PE RATIO(29.24) = STOCK PRICE($161.38) / TTM EPS($5.52)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.